ClinicalTrials.gg
CompletedNCT03938584Updated Jan 26, 2022

The Effect of Vitamin C on Wound Healing In Mandibular Fracture Patients

An interventional study of Vitamin C and Placebo in Vitamin C Deficiency, Smoking and Surgery, sponsored by Hennepin Healthcare Research Institute. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-26.

Sponsored by Hennepin Healthcare Research Institute · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled Oct 2017, registered Apr 2019).
Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this study is to perform a randomized clinical trial to assess the effects of vitamin C versus placebo on wound healing in mandibular fracture patients.

Read the detailed description

In a prospective, randomized clinical trial of de novo mandibular fracture patients requiring intraoral surgical repair with plating, the investigators will:

  1. Compare the effects of supplemental vitamin C to placebo on soft tissue wound healing, measured by a) biomarkers of soft tissue repair (Procollagen I and III, Matrix Metallo-Proteinases 1,2,3 \& 9, C-reactive protein, neutrophil count, Interleukins 6 \& 8, TBARS and TEAC) and b) clinical outcomes (wound dehiscence and Wound Score).

    Hypothesis1: Supplemental vitamin C will improve soft tissue healing post-mandibular fracture, measured by improved procollagen I, other biomarker levels and clinical outcomes, compared to placebo.

    Rationale. The clinical literature describes impaired soft tissue wound healing in mandibular fracture patients, including wound infection, wound dehiscence, and plate exposure. Vitamin C is a necessary co-factor for the production of types I and III collagen, as well as procollagen, the precursor to collagen, via the hydroxylation of proline and lysine. In the setting of vitamin C deficiency, collagen production is abnormal leading to defective vessel and connective tissue formation with degradation of unstable collagen molecules.90-91,34, 63, 108,109

    The investigators will collect a robust set of clinical outcomes including clinician evaluation and Wound Healing Score to measure soft tissue healing. Biomarkers of soft tissue wound healing will be used to measure biochemical healing pathways as well. As a precursor to collagen, procollagen I and III are widely used biomarkers of collagen production in wound healing research. The investigators will assess these levels at baseline and at 3 to 5weeks post-operatively to evaluate the effect of vitamin C on collagen production. In addition, the antioxidant effects of vitamin C are critical during the ordered phases of wound healing, from the inflammatory phase (including the initial hemostatic cascade) to the proliferative phase. Antioxidant depletion during these phases results in imbalanced proteolytic enzyme cascades (including matrix metalloproteinases or MMPs) with resulting tissue destruction as well as an over-exuberant inflammatory milieu. Further, the antioxidant deficit resulting from vitamin C deficiency results in diminished monocyte and neutrophil chemotaxis and diminished bacteriocidal oxidative burst capabilities. Thus, the investigators will additionally measure the effects of vitamin C supplementation on proteolytic enzyme pathways (MMPs) and systemic markers of infection and inflammation (neutrophil count, c-reactive protein level, interleukins (IL) 1 and 6). Finally, the investigators will use indicators of oxidative stress at baseline and 6 weeks to measure the effects of vitamin C supplementation on antioxidant capacity (TBARS and TEAC).

  2. Compare the effects of supplemental vitamin C to placebo on bone repair, measured by a) biomarkers of bone repair (alkaline phosphatase, TRACP 5b, osteocalcin, RANKL, osteoprotegerin, and carboxy terminal collagen crosslinks) and b) clinical outcomes (radiologic imaging and pain).

    Hypothesis 2: Supplemental vitamin C will improve bone healing post-mandibular fracture, measured by improved biomarkers of bone healing and more robust radiological bone imaging, compared to placebo.

    Rationale. A body of literature, from animal studies to randomized clinical trials, supports the notion that vitamin C is necessary for bone health and healing. Multiple animal studies demonstrate that vitamin C promotes bone formation / mineralization, strengthens developing callous, and supports bone maintenance. Further, a number of studies show that supplemental vitamin C prevents fracture in menopausal women and may be protective against arthritis.10,11,12,69 Several well done randomized controlled clinical trials have shown that supplemental vitamin C diminishes regional pain syndrome after distal radius fractures and less robust data suggests this for foot and ankle fractures. Well-done randomized controlled clinical trials are needed to develop Vitamin C guidelines in traumatic facial fracture.

    The investigators will collect a comprehensive set of biochemical, clinical, and radiological outcome measures to evaluate bony healing after mandibular fracture. The biomarker evaluation will include assessment of osteoblast and osteoclast number (alkaline phosphatase and TRACP 5b respectively), osteoblast activity (osteocalcin), osteoclast differentiation (receptor activator for nuclear factor, B ligand or RANKL and osteoprotegerin or decoy receptor for RANKL) and osteoclast activity (carboxy terminal collagen crosslinks). The investigators will measure clinical outcomes about 1 and 3 to 5 weeks postoperatively. Finally, each subject will undergo a non-contrast CT of the mandible 3to 5 weeks post-operatively for radiological evaluation of bone healing. The CT scan may or may not be standard of care.30,36,135

  3. Determine the effects of supplemental vitamin C on soft tissue and bone healing by smoking status in patients with traumatic mandibular fracture.

Hypothesis 3: Current smokers will have a higher prevalence of vitamin C deficiency than nonsmokers at baseline, and vitamin C supplementation will improve soft tissue and bone healing more in smokers than nonsmokers.

Rationale. Despite clinical evidence for smoking-related impairment in wound healing, much is unknown about the pathophysiologic mechanisms underlying this effect.21. It is postulated that after injury, smoking impedes the inflammatory phase of wound healing by diminishing cellular chemotactic responsiveness, migratory function, and oxidative bacterial killing, and by creating an imbalance in protease-protease inhibitor relationships. The proliferative phase of wound healing is also potentially impaired by smoking, with diminished fibroblast proliferation and migration resulting in decreased collagen production.124-30 Increases in oxidative stress and hypoxia further diminish healing in smokers.62,74,76,102 Vitamin C is postulated to be an important contributor to the diminished wound healing evidenced in smokers. Both population and experimental studies have shown smokers are more likely to be deficient in Vitamin C, with 25% of female smokers and 30% of male smokers having severe deficiency. This deficiency is likely secondary to a systemic depletion by the many reactive oxygen species in tobacco smoke as well as a diet lacking antioxidants. The investigators will evaluate the effects of vitamin C on wound healing in current versus non smokers with detailed assessment of tobacco use.

This project assembles a multidisciplinary team with expertise in wound healing, maxillofacial surgery, medical effects of tobacco use, fracture repair, biomechanics of bone, and conduct of clinical trials. The proposed work will define specific effects of supplemental Vitamin C on soft tissue and bone healing, with additional attention to smoking status in patients with mandibular fractures. For the many patients who are at high risk for vitamin C deficiency and poor wound healing, this investigation will provide critical knowledge of the role of oxidative stress and anti-oxidants in the mechanisms of impaired healing. These data will provide pilot data to support randomized controlled trials of interventions to improve post-operative wound healing in patients suffering from mandibular and other traumatic fractures. Establishing the safety and efficacy of supplemental Vitamin C in the peri-operative setting will improve wound healing outcomes for thousands of patients undergoing traumatic fracture surgery and could be a transformative step in treatment guidelines for any smoker undergoing surgery.

02

Conditions studied

  • Vitamin C Deficiency
  • Smoking
  • Surgery
  • Surgery--Complications
  • Wound
  • Wound Complication
  • Wound Infection
  • Wound Dehiscence
  • Wound of Skin
  • Mandible Fracture
  • Mandible Open Fracture
  • Mandible Closed Fracture
  • Mandibular Fractures
  • Ascorbic Acid Deficiency
  • Oxidative Stress
  • Inflammation
03

In context

Smoking

1,509 studies on the registry are indexed under Smoking; 193 are open to participants now.

This study's enrollment of 45 is below the median of 115 across 1,164 interventional studies indexed under Smoking.

Browse Smoking studies →

Lead sponsor

Hennepin Healthcare Research Institute is the lead sponsor of 67 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients age 18 or older with de novo mandibular fracture undergoing surgical repair with an intra-oral incision based approach with plating (ie- not solely mandibular maxillary fixation which requires no surgical incision).,
  • surgery within 7 days of injury.

Exclusion criteria

Exclusion Criteria:

  • cognitive impairment limiting ability to provide
  • pregnancy or nursing
  • a known history of renal insufficiency
  • comminuted fractures,
  • allergy to Vitamin C / placebo components.
  • Isolated subcondylar fractures
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Vitamin C

    Dietary Supplement: Vitamin C

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • Dietary supplementVitamin C

    Just after induction of anesthesia in the OR, subjects will be administered a single intravenous (IV) dose of Vitamin C at 66mg/kg/hr for 2 hours during surgery. Post-operatively (beginning the morning after surgery) Vitamin C Treatment Group subjects will receive a 4 week prescription of oral, liquid Vitamin C, 500mg by mouth two times a day. These dosages are known to be safe and effective.89-91

    Also known as: Ascorbic Acid

  • OtherPlacebo

    Subjects will receive IV placebo (normal saline) identically packaged. Post-operatively Placebo Control Treatment Group participants will receive a 4-week prescription of the aqueous solution base used for the treatment group without the active component (Vitamin C).

06

What researchers measure

Primary outcomes

  1. Procollagen I

    Biomarker of soft tissue repair. Measured in picogram/milliliter (pg/ml) in blood serum.

    Time frame: Blood is obtained the day of surgery and 6 weeks after surgery

  2. Procollagen III

    Biomarker of soft tissue repair. Measured in picogram/milliliter (pg/ml) in blood serum.

    Time frame: Blood is obtained the day of surgery and 6 weeks after surgery

Secondary outcomes

  1. Matrix Metallo-Proteinases 1,2,3 & 9

    Biomarker of soft tissue repair. Measured in picogram/milliliter (pg/ml) in blood

    Time frame: Blood is obtained the day of surgery and 6 weeks after surgery

  2. C-reactive protein

    Biomarker of soft tissue repair. Measured in nanogram/milliliter (ng/ml) in blood

    Time frame: Blood is obtained the day of surgery and 6 weeks after surgery

  3. Neutrophil count

    Biomarker of soft tissue repair. Measured in picogram/milliliter (pg/ml) in blood

    Time frame: Blood is obtained the day of surgery and 6 weeks after surgery

  4. Interleukins 6 & 8

    Biomarker of soft tissue repair. Measured in picogram/milliliter (pg/ml) in blood

    Time frame: Blood is obtained the day of surgery and 6 weeks after surgery

  5. Thiobarbituric acid reactive substances

    Biomarker of soft tissue repair. Measured in micro Molar uM in blood

    Time frame: Blood is obtained the day of surgery and 6 weeks after surgery

  6. Trolox equivalent antioxidant capacity

    Biomarker of soft tissue repair. Measured in nanomol/microliter (nmol/ul) in blood

    Time frame: Blood is obtained the day of surgery and 6 weeks after surgery

  7. alkaline phosphatase

    Biomarker of bone repair. Measured in enzyme unit/liter (U/L) in blood

    Time frame: Blood is obtained the day of surgery and 6 weeks after surgery

  8. Tartrate Resistant Acid Phosphatase 5b

    Biomarker of bone repair. Measured in enzyme unit/liter (U/L) in blood

    Time frame: Blood is obtained the day of surgery and 6 weeks after surgery

  9. osteocalcin

    Biomarker of bone repair. Measured in picogram/milliliter (pg/ml) in blood

    Time frame: Blood is obtained the day of surgery and 6 weeks after surgery

  10. osteoprotegerin

    Biomarker of bone repair. Measured in picogram/milliliter (pg/ml) in blood

    Time frame: Blood is obtained the day of surgery and 6 weeks after surgery

  11. carboxy terminal collagen crosslinks

    Biomarker of bone repair. Measured in nanogram/milliliter (ng/ml) in blood

    Time frame: Blood is obtained the day of surgery and 6 weeks after surgery

  12. Receptor activator of nuclear factor kappa-B ligand

    Biomarker of bone repair. Measured in picogram/milliliter (pg/ml) in blood

    Time frame: Blood is obtained the day of surgery and 6 weeks after surgery

  13. Vitamin C

    Vitamin C levels. Measured in nanomols (nmmol) in blood serum

    Time frame: Blood is obtained the day of surgery and 6 weeks after surgery

  14. Cotinine

    Biomarker of tobacco exposure. Measured in nanograms/milliliter (mg/ml) in blood serum.

    Time frame: Blood is obtained the day of surgery and 6 weeks after surgery

Other outcomes

  1. Wound score

    Wounds are scored from photographs using the InCISE wound score developed by the investigator.

    Time frame: Wounds are analyzed 1 week and 6 weeks after surgery.

07

Study locations

1 site
  • Hennepin Healthcare Research Institute
    Minneapolis, Minnesota 55415, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Jun 2021, 43 months.

Of 401 non-industry interventional studies with no phase under Smoking, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's 43 months is above that.

Counting every sponsor, half of 456 studies reached it within 23 months; a quarter within 8 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2019
First posted
May 6, 2019
StartActual
Oct 12, 2017
Primary completionActual
Jun 1, 2021
CompletionActual
Jun 1, 2021
Last update
Jan 26, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03938584
Lead sponsor
Hennepin Healthcare Research Institute
Collaborators
Regions Hospital, University of Minnesota
Responsible party
Sponsor
First posted
May 6, 2019
Start date
Oct 12, 2017
Primary completion
Jun 1, 2021
Completion
Jun 1, 2021
Last update
Jan 26, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ascorbic Acid

Start the discussion